Spyryx Biosciences, Inc.   Report issue

For profit Phase 2
Founded: Durham NC United States (2013)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2017
NCT03056989
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Spyryx Biosciences, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

spx-101 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1